Dependency on future regulatory approvals for PYRUKYND and potential launches in thalassemia ... sickle cell disease, pediatric PK deficiency, myelodysplastic syndromes (MDS)-associated anemia ...

According to research studies and demographic surveys by the Union Ministry of Tribal Affairs and genetic researchers, sickle cell disease is widespread in many tribal groups of India, especially amon ...

Q4 2024 Earnings Call Transcript February 13, 2025 Operator: Good morning, and welcome to Agios’ Fourth Quarter 2024 ...

Bone marrow transplantation is a costly procedure. Depending on the type of transplant the rate may vary from ₹7 lakh to ₹50 ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Dr Ravinder K Gupta, Dr Akhilpreet Kaur Anemia is a serious global public health problem that particularly affects young ...

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

The company is preparing for two additional commercial launches, with potential approval and launch of Pyrukynd in ...

ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused –– ...

The Ministry of Health in Kuwait has approved the executive regulations for Law No. 31 of 2008, which governs premarital ...

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.